|
|
|
|
|
|
Former president of Cardinal Health’s nuclear and precision health solutions group Tiffany Olson discusses her work on Bayer's Xofigo and how she anticipated the rise of radiopharmaceuticals. |
|
|
|
A robust and competitive M&A environment in 2024 will require dealmakers to exercise greater discernment and discipline in target selection and pricing strategies. |
|
|
|
Life Science Leader catches up with David Younger, cofounder and CEO of A-Alpha Bio, about the promise of molecular glues, the challenges of standing up a new company, and collaborating with Big Pharma. |
|
|
|
|
| 4 Keys To Allo In 2024 With Poseida Therapeutics' Kristin Yarema, Ph.D. | Kristin Yarema, Ph.D., CEO, Poseida Therapeutics, sits down with Cell & Gene: The Podcast Host Erin Harris to discuss four of the biggest challenges the CGT sector faces when it comes to the development of off-the-shelf therapies. Kristin shares how 2024 might see some real progress in allogeneic therapies. Listen now! |
|
|
|
| From Nanoformed Powder To 3D Printable Ink | 3D printing in pharmaceutics is advancing to offer innovative drug delivery applications. Explore the possibilities of forming stable suspension in printing ink from nanoformed materials. |
|
|
|
CONTRIBUTE TO LIFE SCIENCE LEADER |
|
|
|
Think you have a good idea for an article that Life Science Leader readers would find valuable? Read these guidelines first before submitting your idea or your article to our editorial director. |
|
|
| Connect With Life Science Leader: |
|
|
|
